0001645113-22-000017.txt : 20220307 0001645113-22-000017.hdr.sgml : 20220307 20220307181857 ACCESSION NUMBER: 0001645113-22-000017 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220303 FILED AS OF DATE: 20220307 DATE AS OF CHANGE: 20220307 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Benaim Ely CENTRAL INDEX KEY: 0001632237 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37565 FILM NUMBER: 22719684 MAIL ADDRESS: STREET 1: C/O REXAHN PHARMACEUTICALS, INC. STREET 2: 15245 SHADY GROVE ROAD, SUITE 455 CITY: ROCKVILLE STATE: MD ZIP: 20850 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: NovoCure Ltd CENTRAL INDEX KEY: 0001645113 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 000000000 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: NO. 4 THE FORUM STREET 2: GRENVILLE STREET CITY: ST. HELIER STATE: Y9 ZIP: JE2 4UF BUSINESS PHONE: 44 (0)15 3475 6700 MAIL ADDRESS: STREET 1: NO. 4 THE FORUM STREET 2: GRENVILLE STREET CITY: ST. HELIER STATE: Y9 ZIP: JE2 4UF FORMER COMPANY: FORMER CONFORMED NAME: Novocure Ltd DATE OF NAME CHANGE: 20150615 4 1 wf-form4_164669511463233.xml FORM 4 X0306 4 2022-03-03 0 0001645113 NovoCure Ltd NVCR 0001632237 Benaim Ely C/O NOVOCURE INC., 20 VALLEY STREAM PARKWAY, SUITE 300 MALVERN PA 19355 0 1 0 0 Chief Medical Officer Ordinary Shares 2022-03-03 4 A 0 17371 0 A 45570 D Ordinary Shares 2022-03-03 4 S 0 803 74.498 D 44767 D Ordinary Shares 2022-03-04 4 S 0 1510 70.407 D 43257 D Options to Buy Ordinary Shares 80.59 2022-03-03 4 A 0 30422 80.59 A 2023-03-01 2032-02-29 Ordinary Shares 30422.0 30422 D Options to Buy Ordinary Shares 80.59 2022-03-03 4 A 0 5452 80.59 A 2023-03-01 2032-02-29 Ordinary Shares 5452.0 5452 D Represents restricted share units that are scheduled to vest in equal installments on March 1, 2023, 2024 and 2025, subject to the reporting person's continued employment through such dates. Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Options to buy 30,422 ordinary shares will vest and become exercisable in equal installments on each of March 1, 2023, 2024, 2025 and 2026, subject to the reporting person's continued employment through such dates. Options to buy 5,452 ordinary shares will vest and become exercisable in equal installments on each of March 1, 2023 and 2024, subject to the reporting person's continued employment through such dates. By: /s/ Steven Robbins, Attorney in Fact for Ely Benaim 2022-03-07